Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - September 15, 2026 62 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis of the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Non-pharmacological interventions – are they important to patients with cancer? Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer MOST POPULAR ESMO Congress 2023, 20-24 October 2023 Madrid, Spain October 6, 2023 ΚΑΡΚΙΝΟΣ ΤΩΝ ΟΣΤΩΝ February 10, 2019 NCI Part of Federal Effort to Evaluate Antibody Tests for Novel... May 5, 2020 Toothbrushes and ctDNA: Exciting early detection concepts from new teams formed... May 11, 2022 Load more HOT NEWS Skin cancer death rates in men risen dramatically in the last... Five Questions with…Debra. When Used Together, Chemo and Cardiac Drug Improve Chances of Cancer... Five Questions With…Jessica, Katie, and Melanie
